BTG1 Antikörper (N-Term)

Produktnummer ABIN965706

Produktdetails anti-BTG1 Antikörper

Target: BTG1 (B-Cell Translocation Gene 1, Anti-Proliferative (BTG1))

Bindungsspezifität: N-Term

Reaktivität: Human, Maus, Ratte, Huhn

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser BTG1 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC)

Aufreinigung: Purified by antigen-specific affinity chromatography.

Immunogen: Polyclonal antibody produced in rabbits immunizing with a synthetic peptide corresponding to N-terminal residues of human BTG1(B-cell translocation gene 1 protein)

Anwendungsinformationen

Applikationshinweise: ELISA, Western blotting: 1µg/ml for 2hrs.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: This antibody is stored in PBS, 50% glycerol

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Details zu BTG1

Target: BTG1 (B-Cell Translocation Gene 1, Anti-Proliferative (BTG1))

Andere Bezeichnung: BTG1 (BTG1 Produkte)

Synonyme: btg1 antikoerper, AI426953 antikoerper, AW546738 antikoerper, BTG anti-proliferation factor 1 antikoerper, BTG1 protein antikoerper, B-cell translocation gene 1 antikoerper, B cell translocation gene 1, anti-proliferative antikoerper, BTG1 antikoerper, CpipJ_CPIJ001938 antikoerper, btg1 antikoerper, Btg1 antikoerper

Hintergrund: BTG1(B-cell translocation gene 1 protein) is an anti-proliferative protein. Its expression is associated with the early G1 phase of the cell cycle. A chromosomal aberration involving BTG1 may be a cause of a form of B-cell chronic lymphocytic leukemia. BTG1 expression is maximal in the G0/G1 phases of the cell cycle and downregulated when cells progressed through G1. GTG1 negatively regulates cell proliferation. BTG1 is a novel important coactivator involved in the regulation of myoblast differentiation. BTG1 may play an important role in the process of angiogenesis. Antiproliferative proteins of the BTG/Tob family are degraded by the ubiquitin-proteasome system. The C-terminal regions are necessary and sufficient to control the stabilities of BTG1, BTG2, Tob, and Tob2 proteins.

Pathways: Regulation of Muscle Cell Differentiation, Skeletal Muscle Fiber Development